174 related articles for article (PubMed ID: 21034493)
21. The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
Braumann C; Jacobi CA; Rogalla S; Menenakos C; Fuehrer K; Trefzer U; Hofmann M
J Surg Res; 2007 Dec; 143(2):372-8. PubMed ID: 17612567
[TBL] [Abstract][Full Text] [Related]
22. Taurolidine specifically inhibits growth of neuroblastoma cell lines in vitro.
Luckert C; Eschenburg G; Roth B; Appl B; Reinshagen K; Bergholz R
J Pediatr Hematol Oncol; 2014 May; 36(4):e219-23. PubMed ID: 24762556
[TBL] [Abstract][Full Text] [Related]
23. Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo.
Abramjuk C; Bueschges M; Schnorr J; Jung K; Staack A; Lein M
Oncol Rep; 2009 Aug; 22(2):409-14. PubMed ID: 19578784
[TBL] [Abstract][Full Text] [Related]
24. The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death.
Stendel R; Biefer HR; Dékány GM; Kubota H; Münz C; Wang S; Mohler H; Yonekawa Y; Frei K
Autophagy; 2009 Feb; 5(2):194-210. PubMed ID: 19066471
[TBL] [Abstract][Full Text] [Related]
25. The effect of taurolidine on brain tumor cells.
Stendel R; Stoltenburg-Didinger G; Al Keikh CL; Wattrodt M; Brock M
Anticancer Res; 2002; 22(2A):809-14. PubMed ID: 12014655
[TBL] [Abstract][Full Text] [Related]
26. Taurolidine inhibits tumor cell growth in vitro and in vivo.
McCourt M; Wang JH; Sookhai S; Redmond HP
Ann Surg Oncol; 2000 Oct; 7(9):685-91. PubMed ID: 11034247
[TBL] [Abstract][Full Text] [Related]
27. Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo.
Buchholz M; Majchrzak-Stiller B; Hahn S; Vangala D; Pfirrmann RW; Uhl W; Braumann C; Chromik AM
BMC Cancer; 2017 Mar; 17(1):216. PubMed ID: 28340556
[TBL] [Abstract][Full Text] [Related]
28. TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells.
Harati K; Chromik AM; Bulut D; Goertz O; Hahn S; Hirsch T; Klein-Hitpass L; Lehnhardt M; Uhl W; Daigeler A
Anticancer Res; 2012 Jul; 32(7):2967-84. PubMed ID: 22753761
[TBL] [Abstract][Full Text] [Related]
29. Is Taurolidine a candidate for treatment of rheumatoid arthritis?
Marcinkiewicz J; Głuszko P; Kontny E; Kwaśny-Krochin B; Bobek M; Wierzchowski W; Ciszek M; Maśliński W
Clin Exp Rheumatol; 2007; 25(2):211-8. PubMed ID: 17543144
[TBL] [Abstract][Full Text] [Related]
30. Anti-inflammatory effects of taurine derivatives (taurine chloramine, taurine bromamine, and taurolidine) are mediated by different mechanisms.
Marcinkiewicz J; Kurnyta M; Biedroń R; Bobek M; Kontny E; Maśliński W
Adv Exp Med Biol; 2006; 583():481-92. PubMed ID: 17153635
[TBL] [Abstract][Full Text] [Related]
31. Wound healing is not impaired in rats undergoing perioperative treatment with the antineoplastic agent taurolidine.
Braumann C; Guenther N; Pohlenz J; Pfirrmann RW; Menenakos C
Eur Surg Res; 2009; 42(2):91-6. PubMed ID: 19088475
[TBL] [Abstract][Full Text] [Related]
32.
Byer B; Schlein LJ; Rose B; Séguin B
Can J Vet Res; 2020 Apr; 84(2):115-123. PubMed ID: 32255906
[TBL] [Abstract][Full Text] [Related]
33. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.
Calabresi P; Goulette FA; Darnowski JW
Cancer Res; 2001 Sep; 61(18):6816-21. PubMed ID: 11559556
[TBL] [Abstract][Full Text] [Related]
34. The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis.
Braumann C; Henke W; Jacobi CA; Dubiel W
Int J Cancer; 2004 Nov; 112(2):225-30. PubMed ID: 15352034
[TBL] [Abstract][Full Text] [Related]
35. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.
Altomare DA; Rybak SM; Pei J; Maizel JV; Cheung M; Testa JR; Shogen K
BMC Cancer; 2010 Feb; 10():34. PubMed ID: 20137089
[TBL] [Abstract][Full Text] [Related]
36. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells.
Sankpal UT; Goodison S; Jones-Pauley M; Hurtado M; Zhang F; Basha R
Oncotarget; 2017 Feb; 8(9):14593-14603. PubMed ID: 28099934
[TBL] [Abstract][Full Text] [Related]
37. NOB1 is essential for the survival of RKO colorectal cancer cells.
He XW; Feng T; Yin QL; Jian YW; Liu T
World J Gastroenterol; 2015 Jan; 21(3):868-77. PubMed ID: 25624720
[TBL] [Abstract][Full Text] [Related]
38. The effect of Taurolidine on adherent and floating subpopulations of melanoma cells.
Shrayer DP; Lukoff H; King T; Calabresi P
Anticancer Drugs; 2003 Apr; 14(4):295-303. PubMed ID: 12679734
[TBL] [Abstract][Full Text] [Related]
39. Effects of taurolidine and chlorhexidine on SaOS-2 cells and human gingival fibroblasts grown on implant surfaces.
John G; Becker J; Schwarz F
Int J Oral Maxillofac Implants; 2014; 29(3):728-34. PubMed ID: 24818214
[TBL] [Abstract][Full Text] [Related]
40. Taurolidine: preclinical evaluation of a novel, highly selective, agent for bone marrow purging.
Ribizzi I; Darnowski JW; Goulette FA; Akhtar MS; Chatterjee D; Calabresi P
Bone Marrow Transplant; 2002 Feb; 29(4):313-9. PubMed ID: 11896428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
